The race to drug the 'undruggable' KRAS oncogene is entering its next, more elegant phase: degradation. Triana Biomedicines' $120M Series B, closed this week, is a direct wager that its lead molecule, TBN-101, can outmaneuver the current crop of KRAS-G12C inhibitors like Amgen's Lumakras (sotorasib) by eliminating the protein entirely, not just inhibiting its active state. This capital is earmarked for a decisive clinical proof-of-concept readout in non-small cell lung cancer, where early preclinical data suggests TBN-101 drives deeper and more durable tumor regressions than the inhibitor class.
While the investor syndicate remains undisclosed, the size and timing of this round signal sophisticated backers are aligning behind a platform with a clear, de-risked first application. Triana's molecular glue platform, which extends beyond KRAS to other high-value oncology targets, is now funded through critical inflection points. The market context is clear: the first-generation KRAS inhibitors, while groundbreaking, face limitations in efficacy and resistance. This financing underscores a sector-wide pivot towards next-generation modalities that aim not just to block, but to obliterate, foundational cancer drivers. Success for TBN-101 would validate a new therapeutic paradigm and reset competitive expectations in one of oncology's most valuable target spaces.